South Wales, Jan. 16 -- United Kingdom Intellectual Property Office (UKIPO) has registered trademark "BIOLOGY TO BISPECIFIC (B2B)" on Dec. 16, 2025. The details about the trademark application no. UK00004311288 published in the journal no. 2026/003 (Jan. 16).
With Elkington and Fife LLP as representative, Valink Therapeutics Inc. filed the trademark application for the below mentioned good(s)/service(s).
Class 1 : Chemicals for use in industry and science; biological preparations for use in industry and science; proteins for use in science; proteins for use in industry; proteins for detecting antibodies [other than for medical use]; proteins for binding antibodies [other than for medical use]; immunological antibodies, other than for medical use; chemical substances for use in the biotechnological industry; chemicals for use in the pharmaceutical industry; chemical substances for use in the production of drugs; chemicals for use in scientific research [other than medical or veterinary]; chemicals for use in biotechnological product development.
Class 5 : Pharmaceuticals, medical and veterinary preparations; pharmaceutical drugs; pharmaceutical preparations; pharmaceutical products for the treatment of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; anti-cancer drugs; biopharmaceuticals for the treatment of cancer; biological preparations for the treatment of cancer; pharmaceutical preparations for the treatment of tumours; chemotherapeutics; biotechnological preparations for medical use; antibodies.
Class 9 : Scientific, research, weighing, measuring, detecting, testing, inspecting, life-saving and teaching apparatus and instruments; biochemistry apparatus and instruments; chemistry apparatus and instruments; chemical reactors; flow measuring apparatus; laboratory chemical reactors; laboratory incubators [other than for medical use]; computer programs and software relating to biochemistry; chemical engineering software; biochemical engineering software.
Class 41 : Publishing services (including electronic publishing services); publication services; publication of scientific information journals; publishing of scientific papers; publishing of medical publications; publication of educational texts.
Class 42 : Scientific and technological services and research and design relating thereto; drug discovery services; biotechnology research; biological research, clinical research and medical research; scientific research for medical purposes; research and development of vaccines and medicines; scientific research for medical purposes in the area of cancerous diseases; research and development services in the field of antibodies; research and development in the pharmaceutical and biotechnology fields; biotechnology testing; research relating to biotechnology; pharmaceutical drug development services; pharmaceutical products development; development of pharmaceutical preparations and medicines; pharmaceutical research and development; research and development for the pharmaceutical industry; conducting clinical trials for pharmaceutical products; testing of pharmaceuticals; biochemistry drug services; biochemistry consultancy; biochemistry research services; biochemical research and development; research and development in the field of biotechnology; biochemical engineering services; laboratory services; medical research laboratory services; medical laboratories; providing information relating to scientific research in the fields of biochemistry and biotechnology; consultancy in the field of pharmaceutical research; consultancy in the field of biotechnology; consultancy relating to research and development in the field of therapeutics.
Class 44 : Medical services; pharmaceutical services; medical analysis services for cancer diagnosis and prognosis; pharmaceutical consultation; pharmaceutical advice.
The original document can be viewed at: http://www.ipo.gov.uk/cgi-bin/redirect.cgi?type=tmj&link=6¶m1=UK00004311288
Disclaimer: Curated by HT Syndication.
